Spectral Diagnostics is a Phase III company focused on the development of the first theranostic treatment for patients with septic shock. The company is currently seeking FDA approval for Toraymyxin, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. Spectral’s EUPHRATES trial, the world’s first theranostics trial in the area of sepsis, is being directed by the company’s Endotoxin Activity Assay (EAA), the only FDA-cleared diagnostic for the risk of developing sepsis. For more information, visit the company’s Web site at www.spectraldx.com.

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory, and related services to public and private companies across multiple sectors and regions. Rodman also provides research, sales, and trading services. According to Sagient Research Systems, Rodman has been ranked the #1 Placement Agent in terms of the aggregate number of PIPE and RD financing transactions completed every year since 2005. For more information on Rodman & Renshaw, visit www.rodmanandrenshaw.com.

Let us hear your thoughts below: